Warrington-based biopharmaceutical firm Windtree Therapeutics is entering a multimillion-dollar licensing deal with a Chinese drug company for its three new cardiovascular disease drug candidates, writes John George for the Philadelphia Business Journal.  

The agreement with Lee’s Pharmaceutical Ltd. could value up to $138 million along with double-digit royalties on the sales of future products.  

The licensing deal would cover the project in the following places:  

• China
• Macau
• Singapore
• South Korea
• Thailand
• Vietnam
• Brunei
• Myanmar
• Cambodia
• East Timor
• Indonesia
• Laos
• Malaysia
• The Philippines

This project will encompass the progression and market launch of isatroxime for the treatment of acute heart failure and cardiogenic shock. Additionally, it involves a medication aimed at managing high blood pressure and an oral formulation designed to potentially address chronic heart failure. 

Lee will pay for and manage the creation, production, and sale of products in their licensed area.  

Windtree CEO Craig Fraser says that the agreement confirms the strong market potential of istaraxiome to treat heart failure. He added that clinical trial results have demonstrated potential to benefit patients suffering from heart failure and cardiogenic shock.  

Istaroxime is a dual-mechanism therapy that improves heart muscle functions during the “working” and “resting” phase of the heart cycle.  

Read more about Warrington’s biopharmaceutical firm Windtree Therapeutic’s new deal with the Chinese drugmaker in the Philadelphia Business Journal.  

Windtree Therapeutics CEO Craig Fraser – Breaking Down Acute Heart Failure (Clip)